EMA’s CHMP Recommends the Approval of Two Bevacizumab Biosimilars

 EMA’s CHMP Recommends the Approval of Two Bevacizumab Biosimilars

EMA’s CHMP Recommends the Approval of Two Bevacizumab Biosimilars

Shots:

  • The EMA’s CHMP has adopted the positive opinion recommending the approval of two biosimilar bevacizumab medicines, Alymsys and Oyavas for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix
  • Mabxience’s Alymsys and STADA’s Oyavas both show comparable quality, safety & efficacy to Avastin (bevacizumab)
  • Oyavas and Alymsys will be available as 25 mg/ml concentrate for solution for infusion

Source 1, Source 2 ­to­ read full press release/ article | Ref: EMA | Image: Europa EU

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post